In recent years, Adipose-Derived Stromal Cells (ADSCs) have emerged as a potent source of therapeutic cells for the treatment of various clinical indications. This review focusses on ADSCs as a product and the current clinical trial landscape of ADSCs. In-depth emphasis has been given for the clinical and conceptual framework of ADSCs to treat ischemic based indications such as Inflammatory Bowel Dieseases, Cerebrovascular Diseases, Chronic Obstructive Pulmonary Disease, sclerosis based indications such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Systemic Sclerosis, Crohn based Fistula, and Osteoarthritis.